International Immunology, Vol. 15, No. 6, pp. 751-763,
June 2003
© 2003 Japanese Society for Immunology
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
1 Upstate Inc., Charlottesville, VA 22903, USA 2 Large Scale Proteomics Corp., Rockville, MD 20876, USA 3 Department of Chemistry, University of Virginia, Charlottesville, VA 22903, USA 4 Department of Oncology and Pathology, Radiumhemmet, Karolinska Hospital, 17176 Stockholm, Sweden 5 Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, 20133 Milan, Italy 6 Present address: Medarex Inc., 519 Rt. 173 West, Bloomsbury, NJ 08804, USA 7 Present address: MDS Proteomics, Charlottesville, VA 22904, USA 8 Present address: Wyeth-Lederle Viral Vaccine Immunology, Pearl River, NY 10956, USA 9 Present address: IOMAI Corporation, Gaithersburg, MD 20878, USA
Correspondence to: V. Ramakrishna; E-mail: vramakrishna{at}medarex.com
Transmitting editor: H. L. Ploegh
Identifying naturally occurring peptides bound to HLA class I molecules recognized by HLA-restricted cytotoxic T lymphocytes (CTL) is both relevant and central to the development of effective immunotherapeutic strategies against cancer. Several cancer-related genes have been reported for ovarian cancer, but very few are known to be naturally processed T cell epitopes. In the present study we used mass spectrometry to identify 16 novel HLA-A2-bound peptides from HLA-A2+ ovarian cancer cell lines. All 16 peptides are derived from source proteins with diverse functions and marked homology to known proteins found in public databases. Synthetic peptide analogues of identified sequences were found to stabilize HLA-A2.1, albeit with varying affinities. The peptides were found to be antigenic in that a primary CD8+ CTL response could be elicited from normal donor blood. The CTL generated were not only peptide specific, but failed to recognize targets pulsed with control peptides. In addition, recognition of shared HLA-A2-restricted epitopes by these CTL is suggested by their reactivity with a subset of HLA-A2+ tumor lines and freshly isolated cancer cells or cell lines established from peritoneal ascites. These results were further corroborated by competitive inhibition of lysis of an otherwise susceptible cell line in the presence of cold peptide-pulsed targets. Furthermore, lack of recognition of several HLA-A2+ control cell lines or cells isolated from normal ovaries suggests that these peptides are cancer related. These findings broaden the list of CTL-defined antigens that could lead to the development of multi-epitope vaccines for the treatment of ovarian cancer.
Keywords: antigen, cytotoxic T lymphocyte, HLA-A2, mass spectrometry, ovarian carcinoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. K. Scarlett, J. R. Cubillos-Ruiz, Y. C. Nesbeth, D. G. Martinez, X. Engle, A. T. Gewirtz, C. L. Ahonen, and J. R. Conejo-Garcia In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells Cancer Res., September 15, 2009; 69(18): 7329 - 7337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. GIUNTOLI II, T. J. WEBB, A. ZOSO, O. ROGERS, T. P. DIAZ-MONTES, R. E. BRISTOW, and M. OELKE Ovarian Cancer-associated Ascites Demonstrates Altered Immune Environment: Implications for Antitumor Immunity Anticancer Res, August 1, 2009; 29(8): 2875 - 2884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nesbeth, U. Scarlett, J. Cubillos-Ruiz, D. Martinez, X. Engle, M.-J. Turk, and J. R. Conejo-Garcia CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion Cancer Res., August 1, 2009; 69(15): 6331 - 6338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Webb, R. L. Giuntoli II, O. Rogers, J. Schneck, and M. Oelke Ascites Specific Inhibition of CD1d-Mediated Activation of Natural Killer T Cells Clin. Cancer Res., December 1, 2008; 14(23): 7652 - 7658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Huarte, J. R. Cubillos-Ruiz, Y. C. Nesbeth, U. K. Scarlett, D. G. Martinez, R. J. Buckanovich, F. Benencia, R. V. Stan, T. Keler, P. Sarobe, et al. Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity Cancer Res., September 15, 2008; 68(18): 7684 - 7691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-Z. He, V. Ramakrishna, J. E. Connolly, X.-T. Wang, P. A. Smith, C. L. Jones, M. Valkova-Valchanova, A. Arunakumari, J. F. Treml, J. Goldstein, et al. A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin {beta} Clin. Cancer Res., March 15, 2004; 10(6): 1920 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ramakrishna, J. F. Treml, L. Vitale, J. E. Connolly, T. O'Neill, P. A. Smith, C. L. Jones, L.-Z. He, J. Goldstein, P. K. Wallace, et al. Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules J. Immunol., March 1, 2004; 172(5): 2845 - 2852. [Abstract] [Full Text] [PDF]
|
|